These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10392079)

  • 1. The anaemia research nurse in effective multi-disciplinary management of patients on erythropoietin.
    Bennett L
    EDTNA ERCA J; 1998; 24(3):38-9. PubMed ID: 10392079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy of a team-led treatment protocol for the management of renal anaemia.
    Kotwal SS; Lan P; MacLeod A; Jardine M; Snelling P; Craig J; Cass A; Gallagher M
    Nephrology (Carlton); 2013 Oct; 18(10):649-54. PubMed ID: 23889845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin.
    Hörl WH; Vanrenterghem Y; Canaud B; Mann J; Teatini U; Wanner C; Wikström B
    Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii25-32. PubMed ID: 15824127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease.
    Spinowitz BS; Pratt RD;
    Curr Med Res Opin; 2006 Dec; 22(12):2507-13. PubMed ID: 17166333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epoetin delta, erythropoietin produced in a human cell line, in the management of anaemia in predialysis chronic kidney disease patients.
    Kwan JT; Pratt RD;
    Curr Med Res Opin; 2007 Feb; 23(2):307-11. PubMed ID: 17288685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.
    Jacobs C; Frei D; Perkins AC
    Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii3-24. PubMed ID: 15824128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Spanish survey on anaemia management].
    Pérez García R
    Nefrologia; 2003; 23(4):300-11. PubMed ID: 14558329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anemia management protocols: providing consistent hemoglobin outcomes.
    Michael M
    Nephrol Nurs J; 2005; 32(4):423-6. PubMed ID: 16180783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
    Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
    J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A successful anaemia management algorithm that achieves and maintains optimum haemoglobin status.
    Benton S
    J Ren Care; 2008 Jun; 34(2):54-8. PubMed ID: 18498568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin, an update, and where to in the future?
    Sulková S
    EDTNA ERCA J; 1998; 24(3):30-2, 35. PubMed ID: 10392076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous quality improvement (CQI) in rhu-Epo management: the outcome.
    Descamps C; Van Waeleghem JP; Ysebaert D
    EDTNA ERCA J; 1996; 22(3):22-6. PubMed ID: 10723328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caring for the renal failure patient: optimizing iron therapy.
    Folkert VW; Javier AM; O'Mara NB
    Nephrol Nurs J; 2002 Dec; 29(6):586-93; quiz 594-5. PubMed ID: 12596608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaemia management protocols in the care of haemodialysis patients: examining patient outcomes.
    Saunders S; MacLeod ML; Salyers V; MacMillan PD; Ogborn MR
    J Clin Nurs; 2013 Aug; 22(15-16):2206-15. PubMed ID: 23336392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of variability in anemia management on hemoglobin outcomes in ESRD.
    Lacson E; Ofsthun N; Lazarus JM
    Am J Kidney Dis; 2003 Jan; 41(1):111-24. PubMed ID: 12500228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Optimal therapy with erythropoietin (EPO) in patients with renal anemia on hemodialysis therapy].
    Merta M; Sobotová D; Zahálková J; Bitterová Z; Jirka T; Knetl P; Kopenec J; Suchanová J; Vlasák J
    Sb Lek; 2001; 102(1):41-52. PubMed ID: 11830918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anemia management protocols and epoetin alfa administration: an algorithm approach. Case study of the anemic patient.
    Aiello J
    Nephrol Nurs J; 2002 Jun; 29(3):297-300. PubMed ID: 12164081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finding a rational approach to ESA therapy--for payers and patients.
    Messana A
    Nephrol News Issues; 2007 Sep; 21(10):54, 56. PubMed ID: 17918481
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimizing renal anaemia management--benefits of early referral and treatment.
    Stevens P
    Nephrol Dial Transplant; 2005 Sep; 20 Suppl 8():viii22-26. PubMed ID: 16079327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.